Novartis Sandoz May Sell, Halt Portfolio

Dec 15, 2017

Sandoz, Novartis’ generics business, has announced that it is in the process of selling or discontinuing some products in the United States.

“In response to high price pressure, we are optimizing our U.S. portfolio. This includes the sale or discontinuation of certain non-core products and concentration of investment in strategic areas that will drive growth and improve access,” Sandoz told Swiss newspaper, Handelszeitung.

It is still unclear which drugs would be affected by a potential sale.

Third quarter sales for Sandoz were down 10 percent, according to Handelszeitung.

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments